Cell Membrane‐Targeting Type I/II Photodynamic Therapy Combination with FSP1 Inhibition for Ferroptosis‐Enhanced Photodynamic Immunotherapy

Abstract

AbstractAn imbalance in reactive oxygen species (ROS) levels in tumor cells can result in the accumulation of lipid peroxide (LPO) which can induce ferroptosis. Moreover, elevated ROS levels in tumors present a chance to develop ROS‐based cancer therapeutics including photodynamic therapy (PDT) and ferroptosis. However, their anticancer efficacies are compromised by insufficient oxygen levels and inherent cellular ROS regulatory mechanism. Herein, a cell membrane‐targeting photosensitizer, TBzT‐CNQi, which can generate 1O2, •OH, and O2•− via type I/II process to induce a high level of LPO for potent ferroptosis and photodynamic therapy is developed. The FSP1 inhibitor (iFSP1) is incorporated with TBzT‐CNQi to downregulate FSP1 expression, lower the intracellular CoQ10 content, induce a high level of LPO, and activate initial tumor immunogenic ferroptosis. In vitro and in vivo experiments demonstrate that the cell membrane‐targeting type I/II PDT combination with FSP1 inhibition can evoke strong ICD and activate the immune response, which subsequently promotes the invasion of CD8+ T cells infiltration, facilitates the dendritic cell maturation, and decreases the tumor infiltration of tumor‐associated macrophages. The study indicates that the combination of cell membrane‐targeting type I/II PDT and FSP1 inhibition holds promise as a potential strategy for ferroptosis‐enhanced photodynamic immunotherapy of hypoxia tumors.